Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature.

ABSTRACT:

Background

The locally advanced cervical cancer (LACC) of FIGO stage IB3-IIA2 is characterized by large local mass, poor prognosis and survival rate. Tumor response to neoadjuvant chemotherapy for LACC, utilized as a surrogate endpoint, is urgently needed to improve. Given that the antitumor immune response can be suppressed by programed death-1 axis, the treatment paradigm of neoadjuvant chemotherapy combined with immunotherapy has been explored as one of the prognostic treatments in a variety of solid carcinoma. So far, the application of sintilimab, a domestic immune checkpoint inhibitor, combined with neoadjuvant chemotherapy is still limited in LACC, especially in large lesions.

Case description

We present three postmenopausal women diagnosed with FIGO stage IB3-IIA2 ce

SUBMITTER: Liu L 

PROVIDER: S-EPMC10521576 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature